Fairvalue-Calculator Fairvalue-Calculator
EN DE

GeneReach Biotechnology Corp (4171) Fair Value & Analysis

Healthcare · TW · Market cap 991M TWD

Price17.00 TWD
Fair Value2.64 TWD
Upside-84.5%
Quality94/100
Evidence: Low Range 2.42 TWD – 2.96 TWD

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

GeneReach Biotechnology Corp (4171) currently trades at 17.00 TWD, while our model-based Fair Value estimate is 2.64 TWD — implying the stock looks roughly 84.5% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assays, iiPCR Specific Reagents, research reagents and consumables, as well as taco Nucleic Acid Extraction Reagents, IQ REAL Quantitative System, and IQ2000 Detection & Prevention System. It also provides training program; and other services comprising molecular diagnostic technical solutions and laboratory installation, OEM/ODM contract manufacturing, and research collaborations services. The company was founded in 2004 and is headquartered in Taichung, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is GeneReach Biotechnology Corp (4171) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 2.64 TWD versus a price of 17.00 TWD — about −84% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4171?
Our 21-model fair value for GeneReach Biotechnology Corp is 2.64 TWD (as of Jun 25, 2026), built from audited fundamentals. The current price is 17.00 TWD.
What is the quality score of 4171?
GeneReach Biotechnology Corp has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.